"We are pleased to enter this strategic collaboration with PharmaEssentia," Jingsong Wang, M.D., PhD, Chairman of Nona Biosciences, said, " PharmaEssentia'...
UCB's expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum's discovery of t...
Exothera Nucleic Acids, the world's first nucleic acid CRDMO to provide continuous RNA manufacturing services from early discovery up to commercial cGMP, a...
Pharma service provider further expands offerings for clinical development and manufacturing Already 14 customer fills completed in the first quarter of...
The proposed non-clinical studies will investigate pharmacodynamic biomarkers for ST316, a first-in-class β-catenin antagonist, and evaluate the impac...
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...
The grant has been awarded by the Australian Government's National Health and Medical Research Council (NHMRC), and will be matched by the South Australian...
The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete r...
Expanded facility to manufacture mRNA-based therapies and vaccines Researchers at the University of Adelaide will address the design and manufacturi...
The mice model data indicates considerably shorter half life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort...
BBM-H901 is indicated for prophylactic treatment of bleeding in adults with hemophilia B. It is the first adeno-associated virus (AAV) gene therapy for Hem...
Announced an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT045...
Daewoong Pharmaceutical has entered a research collaboration with Sygnature Discovery to expand its global open innovation for novel drug development. On ...
Recommended dose selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a study 23andMe Holding Co. (Nasdaq: M...
© 2025 Biopharma Boardroom. All Rights Reserved.
